Companies: 10,795·Total market cap: $144.5T
Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc.

CLRBNASDAQHealthcare● Active
$2.51
$-0.08(-3.09%)
Market Cap$8012020
P/E Ratio
52W High$14.1
52W Low$2.43
Overview

Cellectar Biosciences, Inc. (CLRB) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · CLRB · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-7.38clrb eps ttm · clrb earnings per shareEarnings history
PE Ratio (TTM)clrb pe ratio ttm · clrb price to earningsPE Ratio deep dive
Revenue (TTM)0.00clrb revenue ttm · clrb annual revenueFull revenue history
Dividend YieldNo Dividenddoes clrb pay dividends · clrb dividend yieldDividend history
Shares Outstanding2.6Mclrb shares outstanding · clrb floatShares outstanding history
Next EarningsAug 13, 2026Est.clrb earnings date · clrb next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
cellectar biosciences, inc. revenue · clrb revenue 2025
FY 2025Net Income-$21.8M▲ +51.12% YoY
202320242025
cellectar biosciences, inc. net income · clrb profit 2025
FY 2025EPS$-8.35▲ +77.14% YoY
202320242025
clrb eps · cellectar biosciences, inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$20.8MEPS: $-7.38View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy8 analystsis clrb a buy · clrb analyst rating
Strong Buy
0
Buy
7
Hold
1
Sell
0
Strong Sell
0
12-Month Price Target
$11.00Low
$2.51Current
$11.00Avg Target338.25% upside
$11.00High
clrb price target · clrb 12 month forecast

Total: 8 · Buy rate: 87.5%

The CLRB analyst consensus is Buy, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month price target is $11.00, representing +338.25% upside from the current price of $2.51.

Stock Performance

Full History
1D-3.09%
1W-10.04%
1M-19.03%
3M-9.06%
YTD-14.92%
1Y-76.43%
5Y-99.45%

About Cellectar Biosciences, Inc.

CEOJames V. Caruso
IPO DateNov 10, 2005
Employees11
CountryUS

Cellectar Biosciences, Inc. Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosi…

what is cellectar biosciences, inc. · clrb stock overview · cellectar biosciences, inc. company profile · who is cellectar biosciences, inc. ceo · clrb NASDAQ · cellectar biosciences, inc. headquarters · cellectar biosciences, inc. business segments

About Stock Overview & Key Data

Cellectar Biosciences, Inc. (CLRB) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Nov 10, 2005. As of the latest trading session, CLRB stock price is $2.51, with a market capitalization of $8.0M. The stock has returned -76.43% over the past 12 months and -14.92% year-to-date.

According to 8 Wall Street analysts, the consensus rating for Cellectar Biosciences, Inc. stock is Buy, with an average 12-month price target of $11.00. In fiscal year 2025, Cellectar Biosciences, Inc. reported revenue of — and net income of -$21.8M. For detailed data — including Cellectar Biosciences, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Cellectar Biosciences, Inc. (CLRB) stock price is $2.51. The stock is traded on NASDAQ under the ticker symbol CLRB. The 52-week range is $2.43 – $14.10.

CLRB stock priceCLRB quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice